Wegovy Side Effects: What to Expect on the Shot or the Tablet

    Short answer

    The most common Wegovy side effects on its FDA label include nausea, diarrhea, vomiting, constipation, stomach pain, altered skin sensations, headache, fatigue and indigestion. In weight trials of the weekly injection, nausea was reported by 44% of adults versus 16% on placebo, mostly while the dose was being increased. The daily tablet's common effects were similar.

    Wegovy now comes as a weekly injection and a daily tablet, and people want to know what each one feels like. The label says stomach effects were most often reported while the dose was being increased. This page covers the trial rates for the injection and the tablet, the serious warnings, and the symptoms that call for your prescriber or emergency care. Everything here comes from the Wegovy prescribing information, revised June 2026.

    Four things the label makes clear

    The short version, from the Wegovy prescribing information, revised 06/2026.

    Nausea affected almost half of adults on the shot

    In the weight trials of the 2.4 mg weekly injection, nausea was reported by 44% of adults compared with 16% on placebo. Diarrhea was reported by 30% and vomiting by 24%.

    Stomach effects were common overall

    About 73% of adults on the injection reported a stomach side effect, compared with 47% on placebo. Severe stomach reactions were reported by 4.1% versus 0.9%.

    The tablet looked similar

    In the trial of the 25 mg daily tablet, the types and frequency of common side effects were similar to the injection. Severe stomach reactions were reported by 2% on the tablet and none on placebo.

    Serious risks come with a boxed warning

    Wegovy carries a boxed warning for thyroid C-cell tumors seen in rodents. The label also lists pancreatitis, gallbladder disease, kidney injury, low blood sugar, a faster heart rate and allergic reactions.

    Common effects in the weight management trials

    The table is the label's Table 3: side effects reported by at least 2% of adults on the 2.4 mg weekly injection, and more often than on placebo, in the weight-reduction trials. The 2.4 mg figure is the label's trial arm, not a recommendation. The label says the 25 mg tablet showed similar types and frequency of common side effects.

    Side effectPlaceboWegovy 2.4 mg injection
    Nausea16%44%
    Diarrhea16%30%
    Vomiting6%24%
    Constipation11%24%
    Stomach pain10%20%
    Headache10%14%
    Fatigue5%11%
    Indigestion (dyspepsia)3%9%
    Dizziness4%8%
    Bloating (abdominal distension)5%7%
    Burping (eructation)under 1%7%
    Low blood sugar (type 2 diabetes, no insulin)2%6%
    Gas (flatulence)4%6%
    Stomach flu (gastroenteritis)4%6%
    Reflux (GERD)3%5%
    Gastritis1%4%
    Viral stomach flu (viral gastroenteritis)3%4%
    Hair loss1%3%
    Altered skin sensations (dysesthesia)1%2%

    Nausea, diarrhea and vomiting

    On the weekly 2.4 mg injection, nausea was reported by 44% of adults versus 16% on placebo. Diarrhea was reported by 30% versus 16%, and vomiting by 24% versus 6%.

    Constipation and stomach pain

    Constipation was reported by 24% of adults on Wegovy compared with 11% on placebo. Stomach pain was reported by 20% compared with 10%.

    Headache, fatigue and dizziness

    Headache was reported by 14% versus 10% on placebo, and fatigue by 11% versus 5%. Dizziness was reported by 8% versus 4% (see GLP-1 dizziness).

    Indigestion, burping and bloating

    Indigestion was reported by 9% of adults on Wegovy compared with 3% on placebo. Burping was reported by 7% versus under 1%, and bloating by 7% versus 5%.

    Hair loss and skin sensations

    Hair loss was reported by 3% versus 1% on placebo and was linked with weight reduction. Altered skin sensations, such as tingling, burning or sensitive skin, were reported by 2% on the 2.4 mg injection versus 1% on placebo in these trials.

    The label says these sensations became more common at higher doses. In the separate 7.2 mg trials, altered skin sensations were reported by 22% on 7.2 mg, 6% on 2.4 mg and 0.3% on placebo.

    Serious warnings to know before you start

    These events are uncommon, but they are why a new or unusual symptom should not always be put down to the medicine.

    Boxed warning: thyroid C-cell tumors

    In rodents, semaglutide caused thyroid C-cell tumors, and it is unknown whether Wegovy does this in people. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2. A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath should be reported to your prescriber.

    Pancreatitis and gallbladder disease

    Acute pancreatitis was confirmed in 4 adults on Wegovy in the weight trials, about 0.2 cases per 100 patient-years. Gallstones were reported by 1.6% on the injection versus 0.7% on placebo, and by 2.5% on the tablet versus 1%.

    Kidney injury and severe stomach effects

    The label warns that stomach effects can be severe and that dehydration from them can cause acute kidney injury. Wegovy is not recommended for people with severe gastroparesis.

    Heart rate, blood pressure and fainting

    Resting heart rate rose by an average of 1 to 4 beats per minute, and the label tells prescribers to check heart rate regularly. Low blood pressure was reported by 1.3% versus 0.4% on placebo, and fainting by 0.8% versus 0.2%.

    Low blood sugar, eyes, allergies, anesthesia and pregnancy

    Low blood sugar is more likely with insulin or a sulfonylurea, and people with diabetic retinopathy should be monitored for changes. The label also lists serious allergic reactions and a risk of food or liquid entering the lungs during anesthesia or deep sedation.

    The label says Wegovy may cause harm to an unborn baby, so tell your prescriber if you are pregnant or planning to be. It also says breastfeeding is not recommended while taking Wegovy tablets.

    When symptoms need medical attention

    This list follows the warnings and Medication Guide in the Wegovy label. It is not a complete list and it is not medical advice: if something feels wrong, call.

    Get emergency help

    Swelling of the face, lips, tongue or throat, trouble breathing, or fainting need emergency care. Severe stomach pain that will not go away, sometimes spreading to the back, also needs urgent attention.

    Call your prescriber

    Contact your prescriber about any of these:

    • Nausea, vomiting or diarrhea that is severe or will not go away, or signs of dehydration.
    • Pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools, which can be gallbladder signs.
    • Shakiness, sweating, dizziness, a fast heartbeat, hunger, headache, blurred vision, confusion or irritability, which can mean low blood sugar, especially with insulin or a sulfonylurea.
    • A racing or pounding heartbeat at rest, or dizziness and feeling faint.
    • Any change in your vision, if you have type 2 diabetes.
    • A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.

    Before any procedure

    Tell your care team you take Wegovy before surgery or any procedure that involves anesthesia or deep sedation. The label asks for this because the stomach empties more slowly.

    Dose questions stay with your prescriber

    Questions about your dose, a step-up or a missed dose belong with your prescriber, and your label has the official missed-dose instructions. This guide shares label facts only and does not give dosing advice.

    How to report a side effect

    The label gives two contacts for reporting a suspected side effect: Novo Nordisk at 1-833-934-6891, or the FDA's MedWatch program at 1-800-FDA-1088.

    Shot vs tablet: how the two forms compare

    With two forms of Wegovy on one label, here is what the label says about each.

    Same active ingredient

    Both forms contain semaglutide, which has an elimination half-life of about 1 week (the semaglutide half-life calculator shows what that means). The label says semaglutide delays gastric emptying, which is linked with fullness and nausea.

    Weekly injection

    The injection is given once a week. The label's schedule starts at 0.25 mg for 4 weeks, with increases every 4 weeks as the prescriber directs; that is the label's schedule, not a plan for you. Stomach effects were most often reported during those increases.

    Daily tablet

    The tablet is taken once daily on an empty stomach. The label's schedule starts at 1.5 mg for 30 days, with increases every 30 days as the prescriber directs. In its trial, 3.4% of people stopped because of stomach effects, compared with 2% on placebo.

    How Ozempic fits in

    Ozempic contains the same semaglutide but is approved for type 2 diabetes, with its own label and trial numbers. For that data, read Ozempic side effects.

    From the makers of this guide

    Log how you feel, day by day

    The label gives trial averages. Your prescriber needs your version: which symptoms, how strong, and how they fall around each dose.

    1. 01

      Built-in symptoms, each with a severity

      The side-effect tracker has built-in GLP-1 symptoms grouped by area, such as injection site, digestive and head and nerves, plus your own, each saved by day with how severe it was. A short daily check-in asks about food noise, side effects and mood, and you can add questions such as energy and sleep.

    2. 02

      Every dose on your schedule

      Log each Wegovy dose on the schedule your prescriber set, and your side-effect trend chart sits on the Dose tab beside your dose history. On iPhone (iOS 17 and later), a Lock Screen Live Activity counts down to the next dose with a one-tap Log button.

    3. 03

      An estimated level chart for the injection

      For the weekly injection, an estimated medication-level chart shows how your logged doses build and fade. It is modeled on the weekly injection, so it is not meant for the daily tablet.

    4. 04

      Meals you can look back on

      Log meals by photo scan, barcode or search in Nutrition, then look back at harder days to see which foods suited you.

    Download on the App StoreGet it on Google Play

    Make the most of your next appointment

    A log is most useful when your prescriber sees it.

    A shareable PDF

    Pep AI builds a PDF report of your doses, injection sites, weight and daily meal totals. Open it at the visit or send it in advance.

    What to ask

    Ask whether your pattern is expected, which signs should prompt a call, and how your other medicines fit in. Your prescriber decides whether anything should change.

    Stay on top of it

    Logging takes seconds once it is part of your day, and the next report is ready when you need it.

    Further reading on Pep AI

    For nausea in particular, read GLP-1 nausea. For an overview across GLP-1 medicines, see GLP-1 side effects, and to log shots and symptoms together, the Wegovy tracker.

    Key takeaways

    • Nausea was reported by 44% of adults on the 2.4 mg weekly injection, versus 16% on placebo; the daily tablet's common effects were similar.
    • Stomach effects were most often reported while the dose was being increased.
    • Altered skin sensations rose with dose: 22% on 7.2 mg, 6% on 2.4 mg and 0.3% on placebo in the 7.2 mg trials.
    • Wegovy carries the boxed thyroid C-cell tumor warning, and its label lists pancreatitis, gallbladder disease, kidney injury and low blood sugar.
    • Dose, step-up and missed-dose questions belong with your prescriber and your label.

    Turn how you feel into something you can show.

    Pep AI logs your Wegovy doses, symptoms with severity, meals, water and weight, and makes a PDF of your doses, weight and meal totals. Download Pep AI on iPhone or Android.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Wegovy (semaglutide) injection and tablets prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
    2. MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    This page summarizes the Wegovy prescribing information (revised 06/2026). It is general information, not medical advice, and does not replace your prescriber or pharmacist. Pep AI is not affiliated with or endorsed by Novo Nordisk. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026